Secondly, the ASM inhibitor desipramine also act as reuptake inhibitor for neurotransmitters in clinical practice, so effects of the neurotransmitters on atherosclerosis cannot be completely ruled out. This evidence concerns the gene SMPD1 and atherosclerosis.